Safety and function of a new pre-vascularized bioartificial pancreas in an allogeneic rat model
© The Author(s) 2020..
Cell encapsulation could overcome limitations of free islets transplantation but is currently limited by inefficient cells immune protection and hypoxia. As a response to these challenges, we tested in vitro and in vivo the safety and efficacy of a new macroencapsulation device named MailPan®. Membranes of MailPan® device were tested in vitro in static conditions. Its bio-integration and level of oxygenation was assessed after implantation in non-diabetic rats. Immune protection properties were also assessed in rat with injection in the device of allogeneic islets with incompatible Major Histocompatibility Complex. Finally, function was assessed in diabetic rats with a Beta cell line injected in MailPan®. In vitro, membranes of the device showed high permeability to glucose, insulin, and rejected IgG. In rat, the device displayed good bio-integration, efficient vascularization, and satisfactory oxygenation (>5%), while positron emission tomography (PET)-scan and angiography also highlighted rapid exchanges between blood circulation and the MailPan®. The device showed its immune protection properties by preventing formation, by the rat recipient, of antibodies against encapsulated allogenic islets. Injection of a rat beta cell line into the device normalized fasting glycemia of diabetic rat with retrieval of viable cell clusters after 2 months. These data suggest that MailPan® constitutes a promising encapsulation device for widespread use of cell therapy for type 1 diabetes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of tissue engineering - 11(2020) vom: 26. Jan., Seite 2041731420924818 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Magisson, Jordan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cell encapsulation |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/2041731420924818 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311029469 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311029469 | ||
| 003 | DE-627 | ||
| 005 | 20231225141356.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/2041731420924818 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1036.xml |
| 035 | |a (DE-627)NLM311029469 | ||
| 035 | |a (NLM)32523669 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Magisson, Jordan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and function of a new pre-vascularized bioartificial pancreas in an allogeneic rat model |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2020. | ||
| 520 | |a Cell encapsulation could overcome limitations of free islets transplantation but is currently limited by inefficient cells immune protection and hypoxia. As a response to these challenges, we tested in vitro and in vivo the safety and efficacy of a new macroencapsulation device named MailPan®. Membranes of MailPan® device were tested in vitro in static conditions. Its bio-integration and level of oxygenation was assessed after implantation in non-diabetic rats. Immune protection properties were also assessed in rat with injection in the device of allogeneic islets with incompatible Major Histocompatibility Complex. Finally, function was assessed in diabetic rats with a Beta cell line injected in MailPan®. In vitro, membranes of the device showed high permeability to glucose, insulin, and rejected IgG. In rat, the device displayed good bio-integration, efficient vascularization, and satisfactory oxygenation (>5%), while positron emission tomography (PET)-scan and angiography also highlighted rapid exchanges between blood circulation and the MailPan®. The device showed its immune protection properties by preventing formation, by the rat recipient, of antibodies against encapsulated allogenic islets. Injection of a rat beta cell line into the device normalized fasting glycemia of diabetic rat with retrieval of viable cell clusters after 2 months. These data suggest that MailPan® constitutes a promising encapsulation device for widespread use of cell therapy for type 1 diabetes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cell encapsulation | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a medical device | |
| 650 | 4 | |a membranes | |
| 650 | 4 | |a pre-vascularization | |
| 700 | 1 | |a Sassi, Aladin |e verfasserin |4 aut | |
| 700 | 1 | |a Xhema, Daela |e verfasserin |4 aut | |
| 700 | 1 | |a Kobalyan, Aram |e verfasserin |4 aut | |
| 700 | 1 | |a Gianello, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Mourer, Brice |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Nguyen |e verfasserin |4 aut | |
| 700 | 1 | |a Burcez, Charles-Thibault |e verfasserin |4 aut | |
| 700 | 1 | |a Bou Aoun, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Sigrist, Séverine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of tissue engineering |d 2010 |g 11(2020) vom: 26. Jan., Seite 2041731420924818 |w (DE-627)NLM206140312 |x 2041-7314 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g day:26 |g month:01 |g pages:2041731420924818 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/2041731420924818 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |b 26 |c 01 |h 2041731420924818 | ||